Amgen Option Alert: Dec 19 $330 Puts Sweep (10) near the Bid: 902 vs 274 OI

Amgen Option Alert: Dec 19 $330 Puts Sweep (10) near the Bid: 902 @ $7.9 vs 274 OI; Ref=$337.28

Amgen Option Alert: Dec 19 $320 Puts at the Bid: 2000 vs 875 OI

Amgen Option Alert: Dec 19 $320 Puts at the Bid: 2000 @ $6.15 vs 875 OI; Ref=$329.325

Amgen Option Alert: Dec 19 $300 Puts at the Bid: 1330 vs 1552 OI

Amgen Option Alert: Dec 19 $300 Puts at the Bid: 1330 @ $4.1 vs 1552 OI; Ref=$319.19

Amgen (NASDAQ:AMGN) Azioni, Quote.MetaTitle.unusual-options

Amgen

Amgen Inc

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Avidity Biosciences

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Amgen (AMGN) Previsione

Notizie

Utili

Quote.Nav.option-chain

Guidance

Dividendi

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Commerci governativi

Rapporto azionario

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
01:14 PMNov 14, 2025	PUT	$330.00	Dec 19, 2025	33	1435	902	524	274	SWEEP	BULLISH
11:37 AMNov 11, 2025	PUT	$320.00	Dec 19, 2025	33	2014	2000	230	875	TRADE	BULLISH
12:30 PMNov 07, 2025	PUT	$300.00	Dec 19, 2025	33	1700	1330	110	1552	TRADE	BEARISH

Comments

Amgen Opzioni Inusuali

Unusual Options Activity for

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO